| Exec date | Filing date | Company | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| Sep 24, 2025 | Sep 26, 2025 | Monopar Therapeutics | Other | Sell | 15.0 | -550,229 | -66.92% | ✗ | $35M |
| Apr 2, 2025 | Apr 4, 2025 | Monopar Therapeutics | Other | Sell | 17.5 | -33,334 | -3.90% | ✗ | $1.2M |
| Mar 31, 2022 | Apr 1, 2022 | Monopar Therapeutics | Chief Scientific Officer | Sell | 52.5 | -471 | -0.01% | ✗ | $1.2K |
| Jan 1, 2022 | Jan 4, 2022 | Monopar Therapeutics | Chief Scientific Officer | Sell | 52.5 | -671 | -0.02% | ✗ | $2.2K |
| Dec 31, 2021 | Jan 4, 2022 | Monopar Therapeutics | Chief Scientific Officer | Sell | 52.5 | -556 | -0.01% | ✗ | $1.8K |
| Sep 30, 2021 | Oct 1, 2021 | Monopar Therapeutics | Chief Scientific Officer | Sell | 52.5 | -471 | -0.01% | ✗ | $2.3K |
| Jun 30, 2021 | Jul 2, 2021 | Monopar Therapeutics | Chief Scientific Officer | Sell | 52.5 | -942 | -0.02% | ✗ | $5.5K |
| Feb 11, 2021 | Feb 16, 2021 | Monopar Therapeutics | Chief Scientific Officer | Sell | 36.3 | -125,000 | -2.84% | ✓ | $1.8M |
| Jan 1, 2021 | Jan 5, 2021 | Monopar Therapeutics | Chief Scientific Officer | Sell | 52.5 | -671 | -0.02% | ✗ | $4.1K |
| Dec 18, 2019 | Dec 20, 2019 | Monopar Therapeutics | Chief Scientific Officer | Buy | 92.5 | +125,000 | 2.92% | ✗ | $1M |